Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders related to neuronal excitation-inhibition imbalance [1][3] - The company will participate in three upcoming investor conferences, providing opportunities for one-on-one meetings with interested investors [1][4] Company Overview - Praxis utilizes genetic insights from epilepsy to develop therapies for CNS disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - The company has a diversified portfolio that includes multiple programs targeting epilepsy and movement disorders, with four clinical-stage product candidates [3] Upcoming Events - Praxis will present at the Baird 2025 Global Healthcare Conference on September 9th from 9:00-9:35am EDT [4] - A fireside chat is scheduled for September 10th at the H.C. Wainwright 27th Annual Global Investment Conference at 8:30am EDT [4] - A virtual corporate presentation will take place on September 18th at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit from 3:00-3:30pm EDT [4]

Another addition to Amneal’s growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen’s Risperdal Consta®. The product is eligib ...

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces recent updates for the ongoing INDP-D101 clinical tri ...

Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 20 ...

Core Insights - Tevogen Bio Holdings Inc. has announced the potential value and forecast for its pipeline product, TVGN 930, aimed at treating non-solid tumor malignancies associated with Epstein-Barr Virus (EBV) [1][2] Financial Projections - The cumulative 5-year top-line revenue forecast for TVGN 930 is approximately $3.5 billion, reflecting the company's innovative drug development model [2] - The risk-adjusted Net Present Value (rNPV) for TVGN 930 is projected to exceed $250 million in the US alone [7] Market Opportunity - There are currently no approved vaccines for EBV, creating a significant therapeutic gap that TVGN 930 aims to fill [4] - The accessible market in the US for TVGN 930 could potentially cover up to 40,000 patients across five rare disease indications [7] Additional Applications - The treatment of multiple sclerosis through tighter EBV control presents an additional opportunity for the product [3]

A BOGO deal, an AI‑powered content challenge, and a chance to win free fire-grilled chicken for life make this September truly Loco EL POLLO LOCO IS GIVING AWAY UP TO $1 MILLION IN FREE CHICKEN FOR NATIONAL CHICKEN MONTH! Photo: El Pollo Loco COSTA MESA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- This September, El Pollo Loco is determined to make National Chicken Month more than just a delicious observance – it is planning to own the month with its “Let’s Get Loco” ethos. And they’re kicking it off by g ...

Strong Loan Growth, Prudent Risk Management, and Regulatory Greenlight Position Credilab for Next Phase of ExpansionKUALA LUMPUR, Malaysia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), a cross-sector platform builder integrating deep technology with financial architecture to enable sovereign-ready digital ecosystems, today announced major milestones for its fintech subsidiary, Credilab Sdn Bhd (“Credilab”), as it strengthens its position as an emergin ...

Core Viewpoint - Petrominera S.E. has decided to terminate the joint venture agreement with Interoil Exploration and Production ASA and Selva Maria Oil S.A. due to alleged failures of the Private Companies to meet their obligations [1][2] Company Overview - Interoil Exploration and Production ASA is a Norwegian exploration and production company listed on the Oslo Stock Exchange, focusing on Latin America [3] - The company operates and holds licenses for several production and exploration assets in Colombia and Argentina, with its headquarters located in Oslo [3] Legal Actions - The company is currently assessing appropriate legal actions with its counsel to challenge the legality of Petrominera's termination and to restore its rights [2]

Core Insights - Highland Copper Company announced positive results from its 2025 metallurgical test work program for the Copperwood Project, indicating significant improvements in copper recovery and process efficiency [1][2][7] Metallurgical Test Work Program - The metallurgical test program initiated in Q1 2025 aimed to enhance the process plant design, incorporating ultrafine flotation technology and optimizing operating costs [2][8] - The redesigned process plant is expected to achieve copper recoveries of 87.6% at lower capital and processing costs, with a smaller scale and reduced power consumption [2][28] - Glencore Technologies is set to provide a performance guarantee related to the improved copper recovery estimates, reinforcing confidence in the test program's robustness [2][61] Engineering and Design Updates - The metallurgical update is a crucial part of Phase 1 detailed engineering, which focuses on finalizing design criteria for the process plant, mine, tailings, and water management [3][5] - Phase 1 engineering is overseen by Dr. Wynand van Dyk, who has extensive experience in mine design and operations [5] Process Circuit Optimization - The new mill-float-mill-float (MF2) circuit design includes a de-sliming stage, which allows for the rejection of up to 25% of mass from primary rougher tailings, leading to energy savings of 10% to 13.7% [8][20][28] - The optimized reagent scheme is projected to reduce operating costs by up to $1.00 per tonne milled while improving environmental, health, and safety performance [8][29] Performance Improvements - Kinetic rougher copper recoveries reached up to 92.4% at a target rougher concentrate grade of 4.5% copper, surpassing the 2018 baseline of 89.7% [8][35] - Locked-cycle tests confirmed up to 85.8% recovery at a 25% copper concentrate grade, demonstrating the effectiveness of the enhanced reagent scheme and MF2 configuration [8][40] Ultrafine Flotation Technology - The introduction of ultrafine flotation technology is expected to enhance the grade-recovery curve, crucial for project economics, while also reducing the processing plant's footprint and environmental impact [48][49] - Pilot-scale tests using the Jameson Cell have shown improved kinetics and recovery potential, affirming the value of this technology in the Copperwood flowsheet [52][60] Next Steps - The next steps include completing lock-cycle variability testing and confirming final process design criteria ahead of initiating Phase 2 of the detailed engineering program [9][8]

Core Insights - Verizon's Chairman and CEO, Hans Vestberg, is scheduled to speak at the Goldman Sachs Communacopia + Technology Conference on September 8, 2025, at 11:50 a.m. ET, with the event being webcasted [1] - Verizon generated revenues of $134.8 billion in 2024, highlighting its significant market presence and commitment to innovation [2] Company Overview - Verizon Communications Inc. is headquartered in New York City and serves customers worldwide, including nearly all of the Fortune 500 [2] - The company focuses on delivering mobility, reliable network connectivity, and security to meet customer demands [2] Media Resources - Verizon's online media center provides access to news releases, stories, and media contacts, available at verizon.com/news [3] - An RSS feed for news releases is also available for subscription [3]